NasdaqGS - Nasdaq Real Time Price USD

COMPASS Pathways plc (CMPS)

Compare

4.2200

-0.1900

(-4.31%)

At close: December 13 at 4:00:02 PM EST

4.3000

+0.08

(+1.90%)

After hours: December 13 at 7:41:55 PM EST

Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

Don't jump in without doing some research first.

Motley Fool 15 days ago

CMPS
-4.31%
Compass Pathways to Participate in December Investor Conferences

LONDON & NEW YORK, November 25, 2024--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings:

Business Wire 19 days ago

CMPS
-4.31%
COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stake

Key Insights Institutions' substantial holdings in COMPASS Pathways implies that they have significant influence over...

Simply Wall St. 20 days ago

CMPS
-4.31%
Compass Pathways to participate in Stifel 2024 Healthcare Conference

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days

GlobeNewswire last month

CMPS
-4.31%
Compass Pathways cuts 30% of workforce on Phase 3 trial delays

Compass Pathways (CMPS) announced yesterday morning with earnings that as a result of changing timelines for its Phase 3 trials, it will be reducing its workforce by approximately 30%, including eliminating some senior management positions, “to further focus the organization and its capital resources on successfully delivering the COMP360 program.” The company’s non-COMP360 preclinical efforts will be stopped and it is “exploring a potential externalization” for its digital health tools. Publish

TipRanks last month

CMPS
-4.31%
Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Despite workforce reductions and trial delays, Compass Pathways PLC (CMPS) maintains a strong cash position and focuses on commercializing COMP360 for treatment-resistant depression.

GuruFocus.com last month

CMPS
-4.31%
Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript

CMPS earnings call for the period ending September 30, 2024.

Motley Fool last month

CMPS
-4.31%
Compass delays anticipated psilocybin readout, cuts staff

The company’s moves come after the FDA seemed to place a new hurdle in the path of psychedelic treatments for mental disorders.

BioPharma Dive last month

CMPS
-4.31%
Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

LONDON & NEW YORK, October 31, 2024--Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progress.

Business Wire last month

CMPS
-4.31%
Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

LONDON, October 24, 2024--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024.

Business Wire last month

CMPS
-4.31%
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

LONDON & NEW YORK, September 23, 2024--Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, announced today that executives from the management team will be participating in a fireside chat at the Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit on September 26, 2024 at 1:20pm ET.

Business Wire 2 months ago

CMPS
-4.31%
Compass Pathways to participate in three investor conferences in September

LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following September investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference: fireside chat at 7:45 am ET on September 4, 2024, and host investor meetingsH. C. Wainwright 26th Annual Global Investment Conference: fireside chat at 9:

GlobeNewswire 3 months ago

CMPS
-4.31%
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks

Despite a rocky start in August, investor sentiment has remained resilient, with the S&P 500 rallying nearly 9% since its August 5th low. This upward momentum has been driven by a series of positive economic data releases, including better-than-expected initial jobless claims and strong retail sales figures. Wall Street also reacted favorably to Federal Reserve Chair Jerome Powell’s comments on Friday, signaling that the Fed is prepared to cut interest rates as the labor market softens and infla

TipRanks 3 months ago

RCKT

RCKTW

CMPS
-4.31%
More promise for psilocybin in depression but safety remains a concern

Psilocybin showed positive signs as a potential treatment for neurological conditions, but safety concerns need to be addressed.

Clinical Trials Arena 3 months ago

GLDAF

CMPS
-4.31%
COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

LONDON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Canaccord Genuity 44th Annual Growth Conference: presentation at 4:30pm ET on August 13, 2024 and host investor meetings. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A rep

GlobeNewswire 4 months ago

CMPS
-4.31%
Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript

CMPS earnings call for the period ending June 30, 2024.

Motley Fool 4 months ago

CMPS
-4.31%
Compass Pathways announces second quarter 2024 financial results and business highlights

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million Conference call August 1 at 8:00 am ET (1:00 pm UK) LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation

GlobeNewswire 4 months ago

CMPS
-4.31%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Tilray’s is expanding in Europe with new milestones in Germany and Portugal. Glass House Brands celebrated court victory with dismissal of Catalyst lawsuit GrowGeneration announced revenue growth amidst store closures. Key Takeaways; Psychedelic Sector Awakn provide updates on a new chemical entity patent portfolio. Compass Pathways received ‘outperform’ rating from RBC. […]

Market Exclusive 4 months ago

TLRY

AWKNF

GHBWF
Compass Pathways to announce second quarter financial results on August 1, 2024

LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, and provide an update on recent business developments, on August 1, 2024. The management team will host a conference call at 8:00 am ET (1:00 pm UK) on August 1, 2024. To access the call, please register

GlobeNewswire 4 months ago

CMPS
-4.31%
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers

Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketamine for depression, highlighting the ongoing interest in non-standard treatment protocols often associated with psychedelic stocks (though ketamine itself isn’t a psychedelic, it does fall within the “alternative therapeutics” camp that psychedelic drug stocks often occupy). Likewise, Congressman Da

InvestorPlace 5 months ago

CMPS
-4.31%
SEEL

Performance Overview

Return	CMPS	MSCI WORLD
YTD	-51.77%	+20.45%
1-Year	-45.34%	+22.00%
3-Year	-82.24%	+21.64%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

COMPASS Pathways plc (CMPS)

Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

Compass Pathways to Participate in December Investor Conferences

COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stake

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways cuts 30% of workforce on Phase 3 trial delays

Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript

Compass delays anticipated psilocybin readout, cuts staff

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Compass Pathways to participate in three investor conferences in September

Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks

More promise for psilocybin in depression but safety remains a concern

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript

Compass Pathways announces second quarter 2024 financial results and business highlights

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Compass Pathways to announce second quarter financial results on August 1, 2024

3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers

Performance Overview